Various treatment regimens for R/R CLL were included, primarily focusing on novel agents, such as BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), PI3K inhibitors (idelalisib, duvelisib), and BCL-2 inhibitors (venetoclax). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.